Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial

OBJECTIVE: To provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Mysler, Eduardo, Moots, Robert J, Wallenstein, Gene V, DeMasi, Ryan, Gruben, David, Soma, Koshika, Iikuni, Noriko, Smolen, Josef S, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802984/
https://www.ncbi.nlm.nih.gov/pubmed/31673419
http://dx.doi.org/10.1136/rmdopen-2019-001040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802984/
https://www.ncbi.nlm.nih.gov/pubmed/31673419
http://dx.doi.org/10.1136/rmdopen-2019-001040

Ejemplares similares